The acquisition, which is consistent with the Gpi Group’s strategic M&A guidelines, entails a significant expansion of the Software BSA, with increased market share in Italy and greater geographic diversification, especially abroad, where the TESI Group realises around 64% of its revenues.
“The acquisition of TESI is a significant junction in the evolutionary path of our Group” – says Fausto Manzana, Chairman and CEO of Gpi – “The strong drive for development abroad, together with the entry into the LIS and RIS/PACS sector, allows us to become a leading international player in the field of diagnostic solutions. The Group’s offerings are enhanced, the synergies with our blood management systems are significant, and the opportunities for innovative integration are many.”
